Clinical Trial Update: Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing safety and immunogenicity of the live attenuated tetravalent Butantan-Dengue vaccine in autoimmune rheumatic diseases; recruitm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Granulomatosis with Polyangiitis
• Idiopathic Inflammatory Myopathies
• Juvenile Idiopathic Arthritis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• Butantan-Dengue vaccine (live attenuated tetravalent) (dengue vaccine, live attenuated, tetravalent)

Snippet

Sponsor: University of Sao Paulo General Hospital | Conditions: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA) | Phase 4 | Status: RECRUITING